Find investors
← Back to all investors
JN
ResearchedAngel Investors

Julius Nestler

Associate

Angel InvestorsSeed Round
Pitch Julius

Get their honest, personalized take on your startup.

Sign in to pitch Julius

At a glance

Full Name
Julius Nestler
Title
Senior Associate
Firm
SK Capital Partners
Firm Type
Private investment / private equity firm
Investment Stage
Control buyouts, recapitalizations, and growth equity investments
Target Company Profile
Businesses in sectors SK Capital knows well where the firm has an actionable plan to substantially improve the company; companies with strong capabilities, products, technologies, sustainable competitive advantages, complexity, and untapped potential
Sector Focus
Material sciences, specialty ingredients, life sciences; historically also specialty materials, chemicals, and pharmaceuticals
Location
New York, New York

Background

Julius Nestler is an investment professional associated with SK Capital Partners in New York. SK Capital announced in January 2022 that Nestler had been promoted to Senior Associate, after joining the firm in 2018 as an Associate. The same announcement describes him as a member of SK Capital’s investment team.

Before SK Capital, Nestler worked as an Investment Banking Analyst in the M&A Advisory Group at PJT Partners. A public FINRA/SEC registration-history mirror lists Julius Nestler at PJT Partners LP with a start date of July 25, 2016, which is consistent with the pre-SK Capital banking role described by SK Capital.

His LinkedIn profile lists SK Capital Partners and WHU - Otto Beisheim School of Management. Publicly available LinkedIn snippets also place him in New York and show language proficiency in English, German, Spanish, and French.

SK Capital itself was founded in 2007 and focuses on material sciences, specialty ingredients, and life sciences. As of December 31, 2025, the firm reported 7 funds, over $9 billion in capital commitments, and more than 20 portfolio companies generating approximately $10 billion in aggregate revenue.

Investment Thesis & Focus

  • SK Capital is not a seed-stage angel investor based on verified public sources; its stated investment activity is private equity, including control buyouts, recapitalizations, and growth equity investments.
  • The firm’s stated sector focus is material sciences, specialty ingredients, and life sciences, with prior wording also emphasizing specialty materials, chemicals, and pharmaceuticals.
  • SK Capital states its investment approach as: “We invest in sectors we know well,” selecting opportunities where it can drive significant improvement.
  • SK Capital says it has two core investment criteria: deep understanding of the business and its markets, and an actionable plan to substantially improve the company with the resources to support that plan.
  • Typical targets include businesses with strong products, capabilities, technologies, and potential to become market leaders with sustainable competitive advantages.
  • The firm is receptive to complexity: it specifically cites companies and situations with complexity where significant untapped potential can be unlocked by an operationally and commercially focused partner.
  • SK Capital invests through Flagship and Catalyst programs; Flagship focuses on upper mid-sized and large companies, while Catalyst is dedicated to smaller and mid-sized companies.

Notable Investments

  • Heubach / Clariant Global Colorants Business: SK Capital and Heubach closed the acquisition of Clariant’s Global Colorants Business in January 2022, creating a global pigments and colorants platform. A public LinkedIn comment on SK Capital’s announcement congratulated Julius Nestler, Jared Kramer, and Santiago Nielsen on the transaction.
  • Halo Pharmaceutical: SK Capital made a controlling strategic growth investment in Halo Pharmaceutical in January 2015; Halo was sold to Cambrex in 2018, then reacquired through Noramco in 2023 and later operated as a standalone CDMO under SK ownership.
  • Archroma: SK Capital acquired Clariant’s Textile Chemicals, Paper Specialties, and Emulsions businesses in September 2013 and combined them into Archroma, a global dyes, pigments, emulsions, and surface-active chemicals business.
  • Axillon Aerospace: SK Capital completed the carve-out of Parker Hannifin’s North America Composites & Fuel Containment Division in November 2024 and renamed it Axillon Aerospace, a provider of engineered carbon fiber composite components and fuel containment solutions.
  • Genetix Biotherapeutics: SK Capital and Carlyle acquired bluebird bio in June 2025; the company rebranded as Genetix Biotherapeutics in September 2025 and focuses on genetic therapies for severe rare diseases.
  • Brothers International: SK Capital acquired a controlling stake in Brothers International in April 2026, a Rochester-based provider of natural fruit ingredients and products for the food and beverage industry.

Unlock the full research

Get how to approach them, recent activity, sources, contact links — plus pitch their AI twin for a candid read on your raise.

One-time. Stays unlocked for you.